Glioblastoma is an aggressive brain cancer that has no cure. A recent chart study of patients with glioblastoma found that taking chemotherapy in the morning was associated with a three- to six-month increase in median survival.
Chemo for glioblastoma enhanced by tapping into cell s daily rhythms - The Source - Washington University in St Louis wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.
Giving chemotherapy in the morning rather than the evening could add a few months to patient survival, a new study shows.
Glioblastoma is an aggressive type of brain cancer with no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years.
Average overall survival for all patients in the study, which appears in
Neuro-Oncology Advances, was about 15 months after diagnosis. Those receiving the chemotherapy drug temozolomide in the morning had an average overall survival of about 17 months post diagnosis, compared with an average overall survival of about 13½ months for those taking the drug in the evening, a statistically significant difference of about 3½ months.
Press Release
Washington University School of Medicine in St. Louis.
Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital have established the Brain Tumor Center, a multidisciplinary practice of physicians and scientists whose mission is to provide leading-edge, patient-centric care for brain tumor patients while also developing transformative basic, translational and clinical research to develop new therapies and improve patient outcomes.
Neurosurgeon and scientist Albert H. Kim, MD, PhD, has been appointed inaugural director of the center, which is based at Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital. He also is a professor of neurosurgery, of genetics, of neurology and of developmental biology.
Giving chemotherapy in the morning can extend survival of glioblastoma patients
An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. While researchers are investigating potential new therapies via ongoing clinical trials, a new study from Washington University in St. Louis suggests that a minor adjustment to the current standard treatment -; giving chemotherapy in the morning rather than the evening -; could add a few months to patients survival.
The study appears online in the journal Neuro-Oncology Advances.
Average overall survival for all patients in the study was about 15 months after diagnosis. Those receiving the chemotherapy drug temozolomide in the morning had an average overall survival of about 17 months post diagnosis, compared with an average overall survival of about 13½ months for those taking the drug in the evening, a statistically